Record Quarterly Revenue and Earnings
Consolidated revenue of $1.08 billion, up 8% year-over-year; non-GAAP EPS of $1.21, up 26% year-over-year; tenth consecutive quarter beating consensus.
Strong Operating Leverage and Margin Expansion
Operating income increased 19% with a 27.5% operating margin; gross margin of 68.1% roughly flat year-over-year; operating expenses rose only 1% reflecting reorganization benefits.
Robust Free Cash Flow and Balance Sheet Improvement
Generated $96 million of free cash flow in Q2; reduced net debt to $2.3 billion; maintained capital allocation focus on growth and buybacks (repurchased $13 million in the quarter).
CooperVision: Market Leadership and Product Momentum
CooperVision revenue $724 million, up 8% (4% organic); Americas +7%, EMEA +6%; daily silicone hydrogel lenses grew 8%; Biofinity up 5% organically; company remains #1 global contact lens maker (~1/3 of wearers).
MiSight (Myopia Control) High Growth
MiSight revenue grew 24% to $32 million with strong uptake in Japan and a successful MyDay MiSight launch in Europe; increased consumer awareness activities during back-to-school season.
CooperSurgical: Strong Performance, Especially Fertility
CooperSurgical revenue $358 million, up 8% (6% organic); fertility grew 13% (10% organic) to $144 million driven by capital equipment, Witness lab tracking and consumables; genomics and capital equipment also contributed.
Strategic Review Attracting Robust Interest
Following settlement of most litigation, management initiated a strategic review of CooperSurgical and reported robust interest from multiple parties for the entire business and parts thereof, with expedited work underway.
Prudent and Clear Guidance with FCF Targets
FY2026 revenue guidance $4.28–4.32 billion (5–6% growth; organic 3.5–4.5%); EPS guidance $4.58–4.66 maintained; 2026 free cash flow outlook increased to roughly $650 million (guidance language around litigation varied in discussion) and reaffirmed $2.2 billion FCF target for 2026–2028.